Cargando…
PD-1/PD-L1抑制剂在非小细胞肺癌中的临床研究进展
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of N...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712270/ https://www.ncbi.nlm.nih.gov/pubmed/31315783 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06 |